SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ICU Medical, Inc. (NASDAQ: ICUI) Accessibility StatementSkip NavigationNEW YORK, March 25, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ICU Medical, Inc. (NASDAQ: ICUI) on behalf of the company's shareholders. The investigation seeks to determine whether ICU Medical's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of ICU Medical, ...

In response to a question about higher oil and fuel prices, management said the company’s exposure is lower than it was when ICU Medical was fully integrated in IV solutions. Jain said ICU Medical now has “only 40%” of that exposure in IV solutions following the joint venture with Otsuka Pharmaceutical, with impacts flowing differently through the income statement. He described higher oil prices as a headwind, noting the company was still working to quantify the effect and identify offsets, but emphasized t ...

ICU Medical Conference Call Summary Company Overview - **Company**: ICU Medical (NasdaqGS:ICUI) - **Event**: 2026 Conference at KeyBanc Healthcare Forum - **Date**: March 18, 2026 Key Industry Insights - **Market Conditions**: The company expects hospital census to remain stable, with no significant growth assumptions for the year [3][4] - **Tariffs and Currency**: The company anticipates no worsening of tariffs and a slightly less favorable currency environment compared to previous assessments [4][5] - **Fuel Prices**: Increased oil prices are seen as a headwind, but the impact is less significant than in previous years due to reduced exposure in the IV solutions business [7][8] Financial Guidance - **EBITDA Guidance**: Initial guidance for 2026 is set between $400 million and $430 million [1] - **Growth Expectations**: Mid-single-digit growth is expected in both consumables and systems segments for the year [10][14] - **Gross Margin Target**: The company aims for a gross margin of around 41% for 2026, with improvements expected from manufacturing consolidations and increased volumes [26][29] Segment Performance Consumables - **Growth Drivers**: The consumables segment has shown strong performance due to effective marketing, increased market share from pump sales, and growth in niche markets like oncology and dialysis [51][52] - **Price Recovery**: The company plans to resume price increases in GPO contracts in the fall of next year to recover inflation costs from previous years [52] Systems - **Pump Segment**: The company has experienced growth in the pump segment, with a focus on refreshing the aging installed base [36][38] - **New Product Launches**: The Plum Solo and Plum Duo pumps are expected to drive future growth, with positive customer feedback on new technology [39][40] Strategic Initiatives - **SKU Rationalization**: The company is focusing on improving profitability in the Vital Care portfolio by eliminating lower-margin products [21][23] - **Software Monetization**: ICU Medical is exploring ways to monetize its software offerings, which have historically been underpriced [47][48] Integration and Synergies - **Smiths Integration**: The integration of Smiths is nearing completion, with significant efforts in manufacturing and IT systems consolidation expected to yield benefits in the near future [57][58] - **Free Cash Flow**: The company aims to improve its free cash flow profile as integration costs decrease, with a goal of returning capital to shareholders [62][63] Market Outlook - **Competitive Landscape**: The company believes that the market is at a critical juncture where many legacy devices need replacement, presenting opportunities for growth [36][38] - **Regulatory Environment**: The company is actively engaging with regulatory bodies regarding new product approvals, with constructive feedback received on submissions [44][45] Conclusion - **Investment Thesis**: ICU Medical maintains a positive outlook on its risk-reward profile for shareholders, emphasizing the potential for EPS growth and improved market positioning as integration efforts conclude and new products are launched [69][70]

ICU Medical FY Conference Summary Company Overview - **Company Name**: ICU Medical - **Ticker**: NasdaqGS:ICUI - **Market Capitalization**: $2.1 billion - **Focus**: Primarily on infusion therapy, which is described as the "plumbing of the hospital" [2][3] - **Revenue Segments**: - **Consumables**: Largest segment, includes items that connect pumps to patients - **Systems**: Includes various types of infusion pumps - **Vital Care**: Ancillary critical care products [3][4] Financial Highlights - **Current Share Price**: Approximately $150 per share - **Equity Value**: About $3.8 billion - **Net Debt**: Just under $1 billion - **Leverage Ratio**: Approximately 2.4 times [6] - **Revenue Distribution**: 2/3 of revenue from North America, primarily the U.S. and Canada [5] - **Product Pricing**: 87%-88% of products are single-use disposables, typically priced under $12 [5] Industry Insights - **IV Therapy Market**: - 90% of hospital patients receive some form of IV therapy [7] - Market characterized by high regulatory barriers, which protect against low-cost competitors [8] - Consolidated industry with few major players [7][8] Growth and Innovation - **Historical Growth**: - Consumables grew 6% in the last year, while systems grew 5% [13] - Previous years showed similar growth rates [13] - **Innovation Strategy**: Focus on incremental innovations rather than major breakthroughs, particularly in consumables [14][15] - **New Product Cycles**: Anticipated launches of new products and software solutions [29] Challenges and Opportunities - **Operational Challenges**: Issues in production affecting the vascular access segment, which is lagging in growth [39] - **Pricing Pressures**: Absorbed inflation costs from 2022 to 2024, with a focus on regaining pricing power [17] - **Regulatory Environment**: Ongoing changes that could impact product development and market entry [25] Strategic Priorities - **Core Revenue Growth**: Aim to maintain consistent growth in consumables and systems [14] - **Innovation Roadmap**: Focus on small, incremental improvements to existing products [14] - **Financial Goals**: Targeting gross margins to improve from 41% to 43% by the end of the next year [27][28] Market Positioning - **Competitive Advantage**: Strong brand recognition and extensive product history in consumables [13] - **Integration of Acquisitions**: Successful integration of Smiths Medical and other acquisitions to enhance product offerings [11][12] Future Outlook - **Market Trends**: Growth in biologics and home infusion markets, which are expanding faster than acute care markets [16] - **Financial Improvement**: Expected improvements in cash flow and earnings per share as operational challenges are addressed [30] Conclusion - **Investment Rationale**: ICU Medical is positioned at an inflection point with new product cycles, improving financials, and a strong recurring revenue base, making it an attractive investment opportunity [30]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - ICU Medical reported fourth-quarter 2025 revenue of $536 million, achieving 2% organic growth and 5% organic growth for the full year, with record performance in consumables and infusion systems [4][7] - The company delivered adjusted EBITDA of $98 million and adjusted earnings per share of $1.91, with gross margins remaining above 40% [3][7] - The 2026 outlook anticipates low- to mid-single-digit organic growth, adjusted EBITDA of $400–430 million, and adjusted EPS of $7.75–8.45, with a focus on improving free cash flow to reduce debt [5][15] Financial Performance - Adjusted SG&A expenses were reported at $113 million, and adjusted R&D expenses were $21 million, totaling adjusted operating expenses of $134 million, which is 25% of revenue [1] - The adjusted gross margin for the quarter was 40.5%, consistent with prior guidance of 40% to 41%, impacted by $11 million in tariff expenses [2][7] - Adjusted EBITDA declined 7% year-over-year from $106 million, primarily due to the deconsolidation of IV Solutions and tariff impacts, representing a $25 million EBITDA headwind [7] Business Segments - Consumables revenue grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic, driven by strong demand in infusion consumables and oncology [8] - Infusion systems revenue increased 3% reported and 1% organic in Q4, with expectations of mid-single-digit organic growth in the near term [16] - Vital Care experienced a 6% organic decline and a 35% reported decline due to the IV Solutions deconsolidation, with management focusing on discontinuing loss-making SKUs [16] Regulatory and Integration Updates - The company closed a broad FDA warning letter related to Smiths Medical and completed major manufacturing and ERP integrations, which are expected to unlock synergies [6][11] - ICU Medical is pursuing 510(k) clearances for key products, including the Medfusion 5000 syringe pump and LifeShield software, as part of its strategy to enhance product offerings [10] 2026 Guidance and Strategic Focus - The company projects full-year adjusted gross margin of around 41%, with improvements expected throughout the year, despite manufacturing inflation and tariff expenses [14] - Free cash flow is expected to improve in 2026, with a focus on debt reduction and a long-term leverage target of 2x by early 2027 [18] - Management indicated that any strategic moves would need to avoid value destruction, particularly in the Critical Care segment, which is seen as less synergistic [19]

Core Viewpoint - ICU Medical reported a revenue of $535.94 million for the quarter ended December 2025, reflecting a 13.8% decline year-over-year, with an EPS of $1.91 compared to $2.11 in the same quarter last year [1] Financial Performance - The reported revenue of $535.94 million exceeded the Zacks Consensus Estimate of $528.97 million, resulting in a surprise of +1.32% [1] - The company achieved an EPS surprise of +13.52%, with the consensus EPS estimate being $1.68 [1] Key Metrics - Revenue from Infusion Systems was $176.3 million, slightly below the average estimate of $177.59 million from two analysts [4] - Revenue from Vital Care reached $79.7 million, surpassing the average estimate of $76.87 million from two analysts [4] - Revenue from Consumables was $284.7 million, exceeding the two-analyst average estimate of $280.64 million [4] Stock Performance - Shares of ICU Medical have returned -2.3% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

分组1 - ICU Medical reported quarterly earnings of $1.91 per share, exceeding the Zacks Consensus Estimate of $1.68 per share, but down from $2.11 per share a year ago, representing an earnings surprise of +13.52% [1] - The company achieved revenues of $535.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.32%, but down from $621.62 million year-over-year [2] - ICU Medical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 6.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.78 on revenues of $522.55 million, and for the current fiscal year, it is $7.96 on revenues of $2.17 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][18] - Adjusted gross margin for Q4 was 40.5%, in line with previous guidance, with adjusted EBITDA decreasing by 7% from $106 million last year [16][18] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth at 7% reported and 6% organic [7][8] - IV systems business grew 3% reported and 1% organic, with LVPs showing low double-digit growth for the year [8][9] - Vital Care decreased 6% organically and 35% reported due to the deconsolidation of IV Solutions, with expectations for flat to slightly down revenue in the near term [10][11] Market Data and Key Metrics Changes - The demand environment remained attractive across geographies, with a notable flu spike in the U.S. towards year-end [6] - The capital environment was stable, with investments being made as needed [7] - Currency fluctuations, particularly the weaker U.S. dollar, positively impacted revenues in selling geographies [7] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation [4][32] - Future growth is expected to be driven by volume increases in core infusion lines and niche categories like oncology [20][21] - The company is working on modernizing its IV Solutions business through a joint venture with Otsuka [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the capital environment and ongoing demand for their products [6][7] - The company anticipates improved free cash flow in 2026, driven by higher earnings and reduced spending on restructuring and integration [26] - Management acknowledged challenges from tariffs and interest rates but believes they can overcome these hurdles [29][34] Other Important Information - The company ended 2025 with $1.3 billion in debt and $308 million in cash, having paid down $303 million in principal during the year [20][27] - Adjusted operating expenses were 25% of revenue, lower than previous guidance, due to cost controls [17] - The company expects to reach a targeted leverage ratio of 2x by early 2027, prioritizing debt paydown with free cash flow [27] Q&A Session Summary Question: Can you discuss the current capital environment and customer decision-making? - Management indicated that the capital environment has been stable, with deals getting done and no significant changes from historical behavior [39] Question: What is the expected impact of new product launches on sales? - Management confirmed that there has been no slowdown in customer interest regarding future product roadmaps, and they are optimistic about upcoming clearances [43][45] Question: How is the company addressing tariff impacts? - Management noted that while there are still challenges related to tariffs, they have implemented structural changes to mitigate these impacts [55] Question: What is the outlook for the Syringe Pumps market? - Management clarified that the Syringe Pumps market is smaller than LVPs but emphasized the importance of having an integrated view for customers [60] Question: What are the margins for the Critical Care business? - Management indicated that most of the Vital Care business likely operates below corporate gross margins, complicating potential divestiture discussions [64]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][16] - Adjusted diluted EPS for Q4 was $1.91, down 9% from $2.11 the previous year [17] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic [7][8] - IV systems business grew 3% reported and 1% organic, with LVPs showing low double-digit growth for the year [8][9] - Vital Care decreased 6% organically and 35% reported due to deconsolidation, remaining flat for the year [10] Market Data and Key Metrics Changes - The demand environment in Q4 was attractive across most geographies, with a notable flu spike in the U.S. towards year-end [6] - The capital environment remained stable, with investments being executed as planned [7] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation [4][30] - Future growth is expected to be driven by volume increases in core infusion lines and niche markets, with a long-term goal of mid-single-digit growth [18][19] - The company is working on integrating manufacturing and IT systems to improve operational efficiency and profitability [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the capital environment and ongoing demand for their products [7][36] - The company anticipates improved free cash flow in 2026, driven by higher earnings and reduced spending on restructuring and integration [24][25] - Management acknowledged challenges from tariffs and interest rates but believes they can overcome these hurdles [27][32] Other Important Information - The company ended 2025 with $1.3 billion in debt and $308 million in cash, having paid down $303 million in principal during the year [18][25] - The company expects to reach a targeted leverage ratio of 2 times by early 2027, prioritizing debt repayment with free cash flow [25][26] Q&A Session Summary Question: Can you discuss the current customer environment for systems? - Management indicated that the capital environment has been stable, with deals being executed as expected [37] Question: What is the expected impact of new product clearances on sales? - Management stated that there has been no slowdown in sales due to pending clearances, and customers are engaged with future product roadmaps [41] Question: How is the company addressing tariff impacts? - Management confirmed ongoing structural changes to mitigate tariff impacts, with some benefits already seen in Q4 [52][53] Question: What is the market size and share for syringe pumps? - Management clarified that the syringe pump market is significantly smaller than LVPs, but they hold a higher market share in syringes [58][59] Question: What are the margins for the Vital Care business? - Management indicated that Vital Care likely operates below corporate gross margins, complicating potential divestiture discussions [63]